SCHEMBL24137459

SCHEMBL24137459

CCc1cnc(OC)c(NS(=O)(=O)c2cccc(C(=O)N=O)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ PIK3CG P48736 2/20 0.43
▸ PIK3CA P42336 3/20 0.42
▸ ACLY P53396 2/20 0.42
▸ MTOR P42345 2/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ HTT P42858 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ METAP2 P50579 1/20 0.41
▸ PIK3CD O00329 1/20 0.40
▸ PIK3CB P42338 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24139765 0.90 SLC40A1 (0.56) SLC40A1ALDH1A1MEN1KMT2APIK3CG
SCHEMBL24139833 0.89 SLC40A1 (0.41) SLC40A1ALDH1A1MEN1KMT2AACLY
SCHEMBL16020309 0.89 ALDH1A1 (0.53) SLC40A1ALDH1A1MEN1KMT2APIK3CG
SCHEMBL24139841 0.88 SLC40A1 (0.46) SLC40A1ALDH1A1MEN1KMT2APIK3CG
SCHEMBL24139956 0.86 PIK3CG (0.49) SLC40A1ALDH1A1MEN1KMT2APIK3CG
SCHEMBL24137196 0.85 ALDH1A1 (0.42) SLC40A1ALDH1A1MEN1KMT2APIK3CG
SCHEMBL24139910 0.81 ALDH1A1 (0.52) SLC40A1ALDH1A1MEN1KMT2APIK3CG
SCHEMBL13976112 0.79 SLC40A1 (0.58) SLC40A1ALDH1A1MEN1KMT2APIK3CG
SCHEMBL24139921 0.79 PIK3CD (0.32) MEN1KMT2APIK3CGPIK3CAPIK3CD
SCHEMBL24140020 0.78 HDAC2 (0.42) ALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2710018-B1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2021-12-29 — — EP disclosed
Send feedback